Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Retained Earnings (2017 - 2025)

Puma Biotechnology's Retained Earnings history spans 9 years, with the latest figure at -$1.3 billion for Q4 2025.

  • For Q4 2025, Retained Earnings fell 21396350.0% year-over-year to -$1.3 billion; the TTM value through Dec 2025 reached -$1.3 billion, down 21396350.0%, while the annual FY2025 figure was -$1.3 billion, 21396350.0% down from the prior year.
  • Retained Earnings reached -$1.3 billion in Q4 2025 per PBYI's latest filing, down from $19000.0 in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $26000.0 in Q3 2024 to a low of -$1.4 billion in Q4 2021.
  • Average Retained Earnings over 5 years is -$740.7 million, with a median of -$1.3 billion recorded in 2021.
  • Peak YoY movement for Retained Earnings: tumbled 136535300.0% in 2023, then soared 750.0% in 2024.
  • A 5-year view of Retained Earnings shows it stood at -$1.4 billion in 2021, then increased by 0.0% to -$1.4 billion in 2022, then increased by 1.58% to -$1.3 billion in 2023, then soared by 100.0% to $6000.0 in 2024, then plummeted by 21396350.0% to -$1.3 billion in 2025.
  • Per Business Quant, the three most recent readings for PBYI's Retained Earnings are -$1.3 billion (Q4 2025), $19000.0 (Q3 2025), and -$14000.0 (Q2 2025).